Liver antigen panel (LSP, LMA, LKM, SLA/LP, BCA) (IIF, IB)

The liver antigen panel is performed for the diagnosis of Autoimmune hepatitis (AIH) and primary biliary cirrhosis of the liver (PBC). Autoimmune hepatitis Hepatitis - an autoimmune disease that results in damage to liver cells, infiltration of inflammatory cells formation foci of necrosis of the liver parenchyma. The disease develops over the years and eventually leads to progressive fibrosis of the liver. Primary biliary cirrhosis of the liver - a disease with an Immune-mediated, resulting in damage to the cholangiocytes (cells of the small bile ducts). A panel of liver antigens specific antibodies against antigens of the liver such as antibodies to liver-specific membrane antigens anti-LSP, antibodies to membrane antigens of of liver cells anti-LMA, hepatic-renal antibodies anti-microsomal anti-LKM, antibodies against soluble liver antigens anti-SLA, antibodies reactive with antigens of the liver and pancreatic LP, and anti-cholecystic antibodies bile duct anti-BCA. Anti-BCA antibodies are produced in about 75% of PBC patients, while the rest are detected in patients with AIH patients. Due to the low specificity of single autoantibodies,  in the diagnosis of liver diseases with an autoimmune diseases, the determination of several antibodies is used simultaneously, which increases the diagnostic sensitivity of the test.